DAIC

JUNE 4, 2024

milla1cf Tue, 06/04/2024 - 20:54 June 4, 2024 — HeartFlow, a leader in cardiovascular healthcare technology, is pleased to announce a key Medicare policy development, which should allow for future expanded patient access to their Plaque Analysis product.

Medicare 104

Medicare Plaque Reimbursement Technology 104

DAIC

JULY 18, 2024

mtaschetta-millane Thu, 07/18/2024 - 10:00 July 18, 2024 — HeartFlow, Inc. , a leader in non-invasive artificial intelligence (AI) heart care solutions, introduced the next generation HeartFlow Plaque Analysis with an interactive experience. medical director of CV imaging, nuclear and CT, Charleston, WV. F.A.C.C.

Coronary Artery Disease 111

Coronary Artery Disease Plaque Technology Medicare 111

DAIC

OCTOBER 15, 2024

tim.hodson Tue, 10/15/2024 - 12:12 Oct. 15, 2024 – Elucid has announced that four of the seven Medicare Administrative Contractors (MACs) will extend coverage for AI-enabled quantitative coronary plaque analysis, including its FDA-cleared PlaqueIQ image analysis software, beginning Nov.

Plaque 52

Plaque Medicare Chest Pain Coronary Artery Disease 52

DAIC

OCTOBER 16, 2024

tim.hodson Wed, 10/16/2024 - 12:36 Oct. 15 , 2024 — Four of the seven Medicare Administrative Contractors (MACs) have released final local coverage determinations (LCD) for AI-Coronary Plaque Analysis (AI-CPA). The four contractors for the U.S. The LCDs have a future effective date of Nov.

CMS 52

CMS Medicare Plaque Chest Pain 52

DAIC

DECEMBER 5, 2024

tim.hodson Thu, 12/05/2024 - 11:59 Dec. 4, 2024 – Cleerly has successfully closed its latest Series C extension funding round, raising a total of $106 million. As we’ve seen with their recent Medicare and CPT I code approvals, this technology is both valuable and ready today in the fight against heart disease.”

Coronary Artery Disease 52

Coronary Artery Disease Medicare Plaque Technology 52

CardiacWire

JUNE 30, 2024

The first half of 2024 is now a wrap, and it was another big one in cardiology. GLP-1s are for CVD too – So far this year GLP-1s have gone from a weight loss and diabetes drug that “might” have cardiovascular benefits to becoming an FDA-approved and Medicare-covered option for CV event reduction.

Tricuspid 59

Tricuspid Reimbursement Medicare Electrophysiology 59

DAIC

JUNE 18, 2024

Image courtesy: Getty Images christine.book Tue, 06/18/2024 - 11:07 June 18, 2024 — Elixir Medical has announced the company’s novel bioadaptive implant, DynamX Sirolimus-Eluting Coronary Bioadaptor System, has been granted Breakthrough Device Designation by the U.S. of the U.S. population. versus 5.5%; p=0.046) respectively.

Coronary Artery Disease 105

Coronary Artery Disease Technology Stents Stent 105